Form 4: Benitec Biopharma Executive Director Acquires 200,004 Stock Options

Megan Boston, Executive Director of Benitec Biopharma Inc., acquired 200,004 stock options on March 6, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 6, 2024, Megan Boston, Executive Director of Benitec Biopharma Inc., acquired 200,004 stock options.
• The options have an exercise price of $5.21.
• The options vest in three equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
• The options expire on March 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's stock option acquisition. While insider transactions can sometimes signal confidence, this is a routine grant with a vesting schedule.

Positives

• The acquisition of stock options by an executive director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by an executive director may have a minor positive impact on shareholder sentiment.

Key Dates